Classes & Events News Feedback Donate

COVID-19 Clinical Research Study Underway at Atlantic Health System, Including Immune Response Study

June 4, 2020

With a large number of COVID-19 patients in NJ, many are enrolling in dynamic, new COVID Research Program clinical study

Clinical trial bottles with labels.

June 4, 2020, Morristown, NJ – As the world clamors for effective treatments and a vaccine against coronavirus 19 (COVID-19), Atlantic Health System is calling on its expertise and national reputation for conducting leading edge clinical trials in oncology, neuroscience, cardiology and other fields. The COVID Research Program is rapidly enrolling patients from New Jersey, which has one of the world’s highest concentrations of COVID-19 patients. Internationally known academic medical centers from other parts of the country are partnering with Atlantic Health System to increase access to innovative trials. 

“Almost overnight, we have built a robust COVID-19 clinical research study,” said Eric Whitman, MD, medical director, Atlantic Health System Cancer Care.  “The caliber of our research program is a result of the hard work and dedication of our physicians, staff, research team, external research partnerships and our reputation,” added Dr. Whitman.

Atlantic Health System Offers Immune Response Study

Atlantic Health System offers a study sponsored by TScan Therapeutics, Inc., a leading T cell therapeutics company in Waltham, Massachusetts, focused on identifying the precise way the human immune system recognizes and responds to infections like COVID-19 or other diseases, like cancers. TScan has developed a novel technology that enables them to identify the natural targets of T cells.  

The purpose of this study is to understand how immune cells mount an immune response to COVID-19. This knowledge will be used in an effort to develop new treatments, vaccines, or diagnostics against COVID-19.  Patients who have recently recovered from a COVID-19 infection have immune cells with the ability to recognize and attack the virus, but it is not clear how immune cells recognize COVID-19. TScan is leveraging its proprietary discovery platform to identify the precise epitopes recognized by T cells in COVID-19 recovered patients. 

“Recovered patients, who choose to volunteer for the TScan clinical research study, will have a one-time blood sample collected so researchers can study how the patient’s T cells recognize and control the virus,” said Principal Investigator Angela Alistar, MD, medical director of the Breakthrough Treatment Center, and of GI Medical Oncology at Morristown Medical Center. “The goal is to use this information to design effective vaccines that will generate appropriate T cell responses in people who have not yet been infected with the virus.” 

This research could be used to generate a vaccine which should provide individuals with robust immunity against any potential future COVID-19 infection. 

The COVID Research Program

Atlantic Center for Research and Atlantic Health System Cancer Care recruited experts in research from the oncology, infectious diseases and research departments at Morristown and Overlook medical centers to form and conduct new studies focused on COVID-19. Once the pandemic hit, the group volunteered to focus on getting a world-class COVID Research Program off the ground.  Other departments soon joined in, including cardiac research, cystic fibrosis research and radiation therapy. 

“The COVID Research Team is fast-tracking a broad range of exciting research studies and doing whatever they can to improve the quality of care for patients,” said Jan Schwarz-Miller, MD, MPH, Chief Medical and Academic Officer, Atlantic Health System.

“Our research team has stepped forward, working long hours to make this happen and rapidly enrolling many of the region’s patients in our clinical trials.” 

Among others, the physician investigators include infectious disease specialists, Jason A. Kessler, MD, from Morristown Medical Center, and Robert J. Roland, DO, from Overlook Medical Center; pulmonary and critical care physicians Lewis Rubinson, MD, PhD and Stanley Fiel, MD from Morristown Medical Center; John Halperin, MD, medical director, Atlantic Health System Neuroscience; Elliot Rosenstein, MD, medical director, Institute for Rheumatic and Autoimmune Diseases, Overlook Medical Center; and several members of Atlantic Medical Group Oncology: Charles M Farber, MD, PhD, medical director of Oncology Research Network Development for Atlantic Health System; Mohamad Cherry, MD, medical director of Hematology, Morristown Medical Center; Sophie Morse, MD, oncology, Overlook Medical Center; and Dr. Alistar and Dr. Whitman. 

Learn more about COVID-19 clinical trials at Atlantic Health System>

About Atlantic Health System

Atlantic Health System has a long-standing tradition of providing exceptional patient outcomes and experiences. Home to seven award-winning hospitals including Morristown Medical Center, the number one hospital in NJ according to U.S. News & World Report, Castle Connolly and Newsweek’s World’s Best Hospitals, the system has been ranked first in New Jersey in consumer preference by Monigle and first among health systems in New Jersey as a “best workplace” by both Modern Healthcare and Fortune Magazine.

Many of the system’s programs have received national accolades and designations, including Morristown Medical Center’s Cardiology and Heart Surgery program ranked among the top 30 in the nation by U.S. News and World Report; Morristown Medical Center’s Orthopedics program ranked among the top 35 in the nation by U.S. News and World Report and Atlantic Health System’s Cancer Care program, New Jersey’s first and only National Cancer Institute National Community Oncology Research Program. Additionally, Atlantic Health System Neuroscience at Overlook Medical Center, working with Atlantic Mobile Health, was the first in the nation to deploy and use portable Telestroke technology in ambulances for routine pre-hospital assessment of stroke patients.

Powered by a passionate workforce of 17,000 team members and 4,800 affiliated physicians dedicated to building healthier communities, Atlantic Health System serves more than half of the state of New Jersey, including 11 counties and 4.9 million people. The system provides care for the full continuum of health needs across a wide array of settings, including Atlantic Medical Group, one of the largest multi-specialty practices in New Jersey with more than 1,000 physicians and providers, 12 urgent care centers, Atlantic Rehabilitation Institute, Atlantic Visiting Nurse and Atlantic Anywhere’s Virtual Visits. Facilitating connections between these services on both land and air is the transportation fleet of Atlantic Mobile Health.

With a clear sense of purpose and an unparalleled culture, Atlantic Health System attracts top leaders in the field of health care, from CEO Brian Gragnolati, who was Chairman of the American Hospital Association in 2019, to the numerous team members who serve as leaders across national clinical associations and research entities.